Navigation Links
Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
Date:11/4/2008

SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, November 11, 2008 at 11:35 a.m. EST (8:35 a.m. PST) at the New York Palace Hotel.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will present an overview of Anadys and its three clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through November 25, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medic
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
2. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
3. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
4. Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
5. Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
6. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
7. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
8. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
10. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
11. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based ... today announced its financial results for the three months ... $861,509 for the three months ended March 31, 2009, ... Net losses were partially offset by grant revenues ...
... PARMA, Italy, May 7 The Parma Group has ... is laying the groundwork to,acquire control of the American ... associated company in the world,s largest,pharmaceuticals market. This presence ... and new projects in the area of respiratory illnesses. ...
... a private company developing the Apollo next-generation fluidics ... F. Marion has accepted a board position to ... was former CEO of Applied Biosystems and today ... backed companies."Andre Marion brings an immense depth of ...
Cached Biology Technology:GeoVax Labs, Inc. Announces First Quarter Financial Results 2GeoVax Labs, Inc. Announces First Quarter Financial Results 3GeoVax Labs, Inc. Announces First Quarter Financial Results 4GeoVax Labs, Inc. Announces First Quarter Financial Results 5The Chiesi Group Lands in the United States 2The Chiesi Group Lands in the United States 3Andre Marion Joins Microchip Biotechnologies' Board of Directors 2
(Date:4/15/2014)... new study from the Women,s Health Initiative (WHI) shows ... symptoms. The study was published online today in ... Society., The authors analyzed the relationship between the blood ... symptoms, including hot flashes, night sweats, sleep disturbance, concentration, ... calcium and vitamin D WHI trial. , There was ...
(Date:4/15/2014)... 2020 how high sea levels will rise into the ... Florida International University scientist Rene Price. , Price is ... Coastal Everglades Long-Term Ecological Research (LTER) site, one of ... reefs to deserts, mountains to salt marshes around the ... one of the most certain consequences of climate change. ...
(Date:4/15/2014)... If an insect drew a line as it ... a tangled mess. But there,s method to that mess, ... engineering and physics, who tries to find simple physical ... https://cornell.box.com/tbeetle , It turns out the tiger beetle, ... reorientation dance as it chases its prey at blinding ...
Breaking Biology News(10 mins):Low Vitamin D may not be a culprit in menopause symptoms 2Long-term predictions for Miami sea level rise could be available relatively soon 2Photo: Tiger beetle's chase highlights mechanical law 2
... , SUNNYVALE, Calif. and ... the technology leader in intelligent video, announced that a major UK ... lane security system using Vidient,s SmartCatch video analytics suite, while a ... another such system.   , The SmartCatch system is a major ...
... COLD SPRING HARBOR, N.Y. (Mon., Feb. 1, ... long been the standard method for identifying genetic regulatory ... control regions. Sequences that are nucleosome-depleted, presumably to provide ... I. Traditional low-throughput methods use Southern blots to ...
... The search for new drug compounds is probably worse ... scientists are limited in the size of the haystacks ... impossible to screen or search through super-large libraries of ... is enormous interest in identifying synthetic molecules that bind ...
Cached Biology News:Vidient SmartCatch Protecting Exit Lanes at Major UK Airport 2Vidient SmartCatch Protecting Exit Lanes at Major UK Airport 3High-throughput analysis of gene regulation, DNA synthesis in Cold Spring Harbor Protocols 2Scripps Research scientists create new way to screen libraries of 10 million or more compounds 2Scripps Research scientists create new way to screen libraries of 10 million or more compounds 3
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
... Mouse monoclonal [SPM278] to 67kD Laminin ... lung carcinoma N592 live cells (Human). ... Not yet tested in other species. ... major glycoproteins of basement membrane, displays multiple ...
Hybridization Buffer 3.6 ml...
...
Biology Products: